

Proposed Recommendations 2015-16 Influenza Season

Lisa Grohskopf, MD, MPH
Influenza Division, CDC

Advisory Committee on Immunization Practices
June 24, 2015

Acknowledgements

Brendan Flannery

Alicia Fry

Jessie Clippard

Swathi Thacker

Sarah Spencer

US Influenza Vaccine Efficacy
Network

Lyn Finelli

Tiffany D'Mello

Lynnette Brammer

Lenée Blanton

Krista Kniss

Rosaline Dhara

Desiree Mustaquim

Michelle Leon

Andrea Steffens

Craig Steffens

Ashley Fowlkes

Michael Jhung

Joe Bresee

Carolyn Bridges

Karen Broder

Jessie Clippard

Frank DeStefano

Sandra Dos Santos Chaves

Paul Gargiullo

Sam Graitcer

Penina Haber

Erin Kennedy

Andrew Kroger

Jeanne Santoli

David Shay

Tom Shimabukuro

Jerry Tokars

Tim Uyeki

Leslie Sokolow

Sonja Olsen

Updated Information for 2015-16

Discussed and Approved at February 2015 ACIP Meeting

- ❑ Reiteration of core guidance that routine annual influenza vaccination is recommended for all persons 6 months of age and older
- ❑ Revision of recommendations regarding use of LAIV for healthy children 2 through 8 years of age
 - No preference is expressed for LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is appropriate.

Further Proposed Updates for 2015-16

- ❑ U.S.influenza vaccine composition for 2015-16
- ❑ Updated influenza vaccine product descriptions, reflecting new licensures, labeling information, and expected availability
- ❑ Revised algorithm for determining number of doses needed for children 6 months through 8 years of age

U.S. Influenza Vaccine Composition for 2015-16

FDA Vaccine and Related Biologic Products Advisory Committee (VRBPAC)—March 4, 2015:

- ❑ An A/California/7/2009 (H1N1)pdm09-like virus;
- ❑ An A/Switzerland/9715293/2013 (H3N2)-like virus
 - replaces A/Texas/50/2012 (H3N2)-like
- ❑ A B/Phuket/3073/2013-like virus (Yamagata lineage)
 - replaces B/Massachusetts/2/2012-like (Yamagata lineage)
- ❑ For quadrivalent vaccines, these viruses PLUS a B/Brisbane/60/2008-like virus (Victoria lineage)

Influenza Vaccine Product Updates for 2015-16

New licensures, labeling information, and expected presentations reflected in text and/or table:


- ❑ Fluzone® Intradermal Quadrivalent IIV
- ❑ Expanded age indication for Flublok® (now 18 and older)
 - Previously noted in online vaccine table and the ACIP Adult Schedule
- ❑ Approval of administration of Afluria® by Stratis® jet injector for persons 18 through 64 years of age
 - Previously noted in online vaccine table
- ❑ Any additional labeling changes arising prior to publication

Determination of Doses Needed for Children Months Through 8 Years of Age

- ❑ Since 2010-2011, algorithm for determining appropriate number of doses in this age group has considered vaccine doses containing A(H1N1)pdm09 separately
 - As a pandemic virus, considered relatively antigenically novel
 - Led to somewhat complicated algorithm(s)
- ❑ This virus has been represented by an A/California/7/2009(H1N1)-like virus in trivalent and quadrivalent vaccines since 2010-2011
 - Likely a diminishing number of children each season who have not been exposed to this virus
- ❑ The WG proposes language that would eliminate separate counting of doses containing A(H1N1)pdm09-type virus
 - Single simplified algorithm

Determination of Doses Needed for Children Months Through 8 Years of Age

Proposed Approach for 2015-16 Season (ORIGINAL VERSION)




* The two doses need not have been received during the same season.

† Doses should be administered ≥ 4 weeks apart

Determination of Doses Needed for Children Months Through 8 Years of Age

Proposed Approach for 2015-16 Season (**EDITED PER ACIP DISCUSSION**)



* The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered ≥ 4 weeks apart

Thank You

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

